Vanguard Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $10.9B | Sell |
24,105,823
-111,042
| -0.5% | -$47.9M | 0.16% | 103 |
|
|
2025
Q3 | $9.48B | Buy |
24,216,865
+243,088
| +1% | +$102M | 0.14% | 118 |
|
|
2025
Q2 | $10.7B | Buy |
23,973,777
+482,616
| +2% | +$222M | 0.17% | 98 |
|
|
2025
Q1 | $11.4B | Buy |
23,491,161
+232,873
| +1% | +$109M | 0.21% | 84 |
|
|
2024
Q4 | $9.37B | Buy |
23,258,288
+98,654
| +0.4% | +$45.7M | 0.16% | 100 |
|
|
2024
Q3 | $10.8B | Buy |
23,159,634
+184,113
| +0.8% | +$88.4M | 0.19% | 86 |
|
|
2024
Q2 | $10.8B | Buy |
22,975,521
+299,003
| +1% | +$130M | 0.21% | 81 |
|
|
2024
Q1 | $9.48B | Buy |
22,676,518
+394,338
| +2% | +$167M | 0.19% | 93 |
|
|
2023
Q4 | $9.07B | Buy |
22,282,180
+298,824
| +1% | +$110M | 0.2% | 87 |
|
|
2023
Q3 | $7.64B | Buy |
21,983,356
+87,397
| +0.4% | +$30.6M | 0.19% | 92 |
|
|
2023
Q2 | $7.71B | Buy |
21,895,959
+49,807
| +0.2% | +$16.8M | 0.18% | 92 |
|
|
2023
Q1 | $6.88B | Buy |
21,846,152
+299,249
| +1% | +$89.8M | 0.18% | 101 |
|
|
2022
Q4 | $6.22B | Buy |
21,546,903
+414,567
| +2% | +$126M | 0.17% | 111 |
|
|
2022
Q3 | $6.12B | Buy |
21,132,336
+293,861
| +1% | +$84.5M | 0.18% | 95 |
|
|
2022
Q2 | $5.87B | Buy |
20,838,475
+365,004
| +2% | +$97.7M | 0.17% | 106 |
|
|
2022
Q1 | $5.34B | Buy |
20,473,471
+317,629
| +2% | +$75.4M | 0.13% | 139 |
|
|
2021
Q4 | $4.43B | Sell |
20,155,842
-286,849
| -1% | -$55.8M | 0.1% | 185 |
|
|
2021
Q3 | $3.71B | Buy |
20,442,691
+193,473
| +1% | +$37.8M | 0.09% | 205 |
|
|
2021
Q2 | $4.08B | Sell |
20,249,218
-166,493
| -0.8% | -$34.8M | 0.1% | 180 |
|
|
2021
Q1 | $4.39B | Sell |
20,415,711
-17,339
| -0.1% | -$3.81M | 0.12% | 145 |
|
|
2020
Q4 | $4.83B | Sell |
20,433,050
-256,869
| -1% | -$58.9M | 0.14% | 128 |
|
|
2020
Q3 | $5.63B | Sell |
20,689,919
-183,238
| -0.9% | -$50.6M | 0.19% | 91 |
|
|
2020
Q2 | $6.06B | Buy |
20,873,157
+264,218
| +1% | +$71.6M | 0.21% | 78 |
|
|
2020
Q1 | $4.9B | Buy |
20,608,939
+514,705
| +3% | +$118M | 0.21% | 90 |
|
|
2019
Q4 | $4.4B | Buy |
20,094,234
+166,055
| +0.8% | +$33.6M | 0.15% | 118 |
|
|
2019
Q3 | $3.38B | Buy |
19,928,179
+266,379
| +1% | +$47.1M | 0.13% | 163 |
|
|
2019
Q2 | $3.61B | Buy |
19,661,800
+180,239
| +0.9% | +$31.5M | 0.14% | 138 |
|
|
2019
Q1 | $3.58B | Buy |
19,481,561
+92,370
| +0.5% | +$17.1M | 0.14% | 131 |
|
|
2018
Q4 | $3.21B | Buy |
19,389,191
+613,939
| +3% | +$106M | 0.14% | 129 |
|
|
2018
Q3 | $3.62B | Buy |
18,775,252
+213,550
| +1% | +$38M | 0.14% | 127 |
|
|
2018
Q2 | $3.15B | Buy |
18,561,702
+223,136
| +1% | +$34.6M | 0.13% | 134 |
|
|
2018
Q1 | $2.99B | Buy |
18,338,566
+404,062
| +2% | +$66M | 0.13% | 141 |
|
|
2017
Q4 | $2.69B | Buy |
17,934,504
+322,457
| +2% | +$47.7M | 0.12% | 169 |
|
|
2017
Q3 | $2.68B | Buy |
17,612,047
+632,175
| +4% | +$95.2M | 0.13% | 154 |
|
|
2017
Q2 | $2.19B | Buy |
16,979,872
+504,982
| +3% | +$60.8M | 0.11% | 187 |
|
|
2017
Q1 | $1.8B | Buy |
16,474,890
+560,796
| +4% | +$49.4M | 0.09% | 227 |
|
|
2016
Q4 | $1.17B | Buy |
15,914,094
+312,003
| +2% | +$25.4M | 0.07% | 338 |
|
|
2016
Q3 | $1.36B | Buy |
15,602,091
+336,916
| +2% | +$31.8M | 0.08% | 273 |
|
|
2016
Q2 | $1.31B | Buy |
15,265,175
+329,337
| +2% | +$28.5M | 0.08% | 261 |
|
|
2016
Q1 | $1.19B | Buy |
14,935,838
+432,369
| +3% | +$39.1M | 0.08% | 280 |
|
|
2015
Q4 | $1.82B | Buy |
14,503,469
+401,421
| +3% | +$48.5M | 0.12% | 156 |
|
|
2015
Q3 | $1.47B | Buy |
14,102,048
+256,109
| +2% | +$32.9M | 0.11% | 191 |
|
|
2015
Q2 | $1.71B | Buy |
13,845,939
+328,820
| +2% | +$41.4M | 0.12% | 171 |
|
|
2015
Q1 | $1.59B | Sell |
13,517,119
-1,984,568
| -13% | -$238M | 0.11% | 192 |
|
|
2014
Q4 | $1.84B | Sell |
15,501,687
-1,734,646
| -10% | -$195M | 0.13% | 148 |
|
|
2014
Q3 | $1.94B | Buy |
17,236,333
+533,587
| +3% | +$50.8M | 0.15% | 130 |
|
|
2014
Q2 | $1.58B | Buy |
16,702,746
+314,096
| +2% | +$22M | 0.12% | 160 |
|
|
2014
Q1 | $1.16B | Buy |
16,388,650
+656,739
| +4% | +$52M | 0.1% | 216 |
|
|
2013
Q4 | $1.17B | Buy |
15,731,911
+322,023
| +2% | +$22.4M | 0.1% | 202 |
|
|
2013
Q3 | $1.17B | Buy |
15,409,888
+3,842,902
| +33% | +$306M | 0.11% | 168 |
|
|
2013
Q2 | $924M | Buy |
+11,566,986
| New | +$852M | 0.1% | 210 |
|
Other funds holding VRTX
Vanguard Group's VRTX Position: Q4 2025 in Review
Vanguard Group reduced its Vertex Pharmaceuticals (VRTX) stake by 0.46% in Q4 2025, selling an estimated $47.9M and leaving 24,105,823 shares worth $10.9B. The position accounts for 0.16% of the portfolio, ranked #103.
Vanguard Group first reported a position in VRTX in Q2 2013 and has held it in 51 quarters since. The position peaked at $11.4B in Q1 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.
- Vanguard Group held 24,105,823 shares of Vertex Pharmaceuticals worth $10.9B as of Q4 2025.
- Vanguard Group sold 111,042 Vertex Pharmaceuticals shares in Q4 2025, an estimated $47.9M.
- Vertex Pharmaceuticals made up 0.16% of Vanguard Group's portfolio in Q4 2025, its #103 holding.
- Vanguard Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Vertex Pharmaceuticals position peaked at $11.4B in Q1 2025.
- 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.